Northside Hospital–Atlanta, a member of the Addario Lung Cancer Medical Institute consortium will be one of the initial hospitals to take part in a groundbreaking study to measure and monitor lung cancer patient’s response to treatments using blood-based biopsies, according to a press release.
“Testing for genetic markers in a lung cancer patient’s blood during their treatment will ensure more informed patient and physician decision-making and establish a lung cancer standard of care,” said Tony Addario, chair and CEO of ALCMI. “An estimated 80 percent of cancer patients receive their care in community cancer centers, such as Northside Hospital, versus large academic institutions. It is our goal to bring cutting-edge clinical trials to patients in their backyard by collaborating with community hospitals, thereby giving more patients access to innovative cancer research, studies and clinical trials.”
This year nearly 250,000 Americans will be diagnosed with lung cancer and an estimated 165,000 will die from the disease. Two thirds of lung cancer patients never smoked or quit decades ago. “Our collective goal is to make lung cancer a chronically managed disease by combining scientific expertise found at leading academic institutions with patient access through a network of community cancer centers – accelerating novel research advancements to lung cancer patients,” Addario said.
ALCMI, working in tandem with its collaborative partner foundation, the Bonnie J. Addario Lung Cancer Foundation power research in genetic testing, therapeutic discoveries, targeted treatments and early detection for lung cancer. ALCMI overcomes barriers to collaboration via a world-class team of investigators from 26-member institutions in the United States such as Northside Hospital-Atlanta, and additional collaborators in France, Italy, Spain and the United Kingdom, supported by ALCMI’s dedicated, centralized research infrastructures such as centralized tissue banks and data systems.
About the Author
